Immune modulatory effects of oncogenic KRAS in cancer
Abstract: Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumour microenvironment (TME). Here, we discuss recent reports connecting KRAS mutations with tumour-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME. We discuss the preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Nature communications. - 11, 1 (2020) , 5439, ISSN: 2041-1723
- Schlagwort
-
Immunologe
Tumorimmunologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- DOI
-
10.1038/s41467-020-19288-6
- URN
-
urn:nbn:de:bsz:25-freidok-1694238
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hamarsheh, Shaima'a
- Groß, Olaf
- Brummer, Tilman
- Zeiser, Robert
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Immune checkpoint inhibitor induced neurocognitive deficits in patients
The role of the MDM2/p53 axis in anti-tumor immune responses
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Advances in understanding the pathogenesis of graft‐versus‐host disease
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of purine metabolites as DAMPs in acute graft-versus-host disease
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
NLRP3 inflammasome activation in cancer: a double-edged sword
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Chimeric antigen receptor T cells for acute myeloid leukemia
Immune checkpoint inhibitor induced neurocognitive deficits in patients
The role of the MDM2/p53 axis in anti-tumor immune responses
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Advances in understanding the pathogenesis of graft‐versus‐host disease
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of purine metabolites as DAMPs in acute graft-versus-host disease
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
NLRP3 inflammasome activation in cancer: a double-edged sword
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Chimeric antigen receptor T cells for acute myeloid leukemia
Immune checkpoint inhibitor induced neurocognitive deficits in patients
The role of the MDM2/p53 axis in anti-tumor immune responses
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Advances in understanding the pathogenesis of graft‐versus‐host disease
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
The role of purine metabolites as DAMPs in acute graft-versus-host disease
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
NLRP3 inflammasome activation in cancer: a double-edged sword
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation